ADVANTAGENE, INC

AUBURNDALE, MA · Biotech · Private

Aglatimagene besadenovec (AdV-tk), an oncolytic adenovirus for local delivery combined with prodrug (Gene Mediated Cytotoxic Immunotherapy, GMCI), administered with chemoradiation for pancreatic cance

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Headquarters
AUBURNDALE, MA
Latest Form D
$28.7M, Nov 2018
Total capital
$39.6M
Federal grants
$3.6M
5 awards · 2015–2021
Rank in peer group#246 of 479
Private capital raised
$35.9M
3 Form D · last Nov 2018
95 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
5 pending

Capital timeline

2015201620172018201920202021FEDERAL ↑EQUITY ↓Cumulative $39.6M$300K$2M$116K$611K$611K1st Form D$2.2M2nd Form D$5M3rd Form D$28.7M

Latest events

  • Federal grantHealth and Human S · Phase II · Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$611K
  • Federal grantHealth and Human S · Phase II · Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$611K
  • Federal grantHealth and Human S · Phase II · Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$116K
  • Private capital raisedForm D · SEC · 3rd filing$28.7M
  • Federal grantHealth and Human S · Phase II · Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$2M
  • Private capital raisedForm D · SEC · 2nd filing$5M
  • Federal grantHealth and Human S · Phase II · Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$300K
  • Private capital raisedForm D · SEC · 1st filing$2.2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3391CERo Therapeutics, Inc.—$44.6M
3392Forte Biosciences—$44.1M
3393Oncotelic Therapeutics, Inc.—$40.3M
3394ADVANTAGENE, INC—$35.9M
3395Allarity Therapeutics, Inc.—$26.9M
3396OTHRAM, INC.—$31.7M
3397Lakewood-Amedex, Inc.—$30M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 12 related persons
  • Laura AguilarExecutive Officer
  • Estuardo Aguilar-CordovaDirector · Executive Officer
  • Edward BenzDirector
  • Mitchell FinerDirector
  • Paul ManningDirector
  • Chris MartellDirector
  • Glenn MattesDirector
  • Udi MeravDirector
Show all 12 people
  • Fred MermelsteinDirector
  • Stephen RocamboliExecutive Officer
  • Alan SmithDirector
  • Sean StalfortDirector

Patents

USPTO · 0 granted of 5
  • Methods Of Treating TIM-3 Elevationapplication
  • Gmci And Ddri Combination Therapy For Treating Cancerapplication
  • Methods Of Treating TIM-3 Elevationapplication
  • Methods Of Treating TIM-3 Elevationapplication
  • A Mixed Complementary Viral Vector For Gene Therapyapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.